(2S,1′S,2′R,3′R)-2-(2′-Carboxy-3′ -hydroxymethylcyclopropyl) Glycine Is a Highly Potent Group 2 and 3 Metabotropic Glutamate Receptor Agonist with Oral Activity

Journal of Medicinal Chemistry

Volumn 47, Issue 2, 2004, Pages 456-466

  Collado, Iván ^a   Pedregal, Concepción ^a   Bueno, Ana Belén ^a   Marcos, Alicia ^a   González, Rosario ^a   Blanco Urgoiti, Jaime ^b   Pérez Castells, Javier ^b   Schoepp, Darryle D ^c   Wright, Rebecca A ^c   Johnson, Bryan G ^c   Kingston, Ann E ^c   Moher, Eric D ^c   Hoard, David W ^c   Griffey, Kelly I ^c   Tizzano, Joseph P ^c,d  

^a ELI LILLY AND COMPANY   (Spain)

^b UNIVERSIDAD SAN PABLO CEU   (Spain)

^c ELI LILLY AND COMPANY   (United States)

^d DOV Pharmaceuticals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2' CARBOXY 3' HYDROXYMETHYLCYCLOPROPYL)GLYCINE; GLYCINE DERIVATIVE; METABOTROPIC RECEPTOR AGONIST; UNCLASSIFIED DRUG; 2-(2'-CARBOXY-3'-HYDROXYMETHYLCYCLOPROPYL)GLYCINE; CYCLIC AMP; DRUG DERIVATIVE; GLYCINE; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; MALE; MOTOR ACTIVITY; MOUTH CAVITY; NONHUMAN; PSYCHOSIS; RAT; STARTLE REFLEX; SUBSTITUTION REACTION; ANIMAL; BIOSYNTHESIS; BRAIN CORTEX; CHEMISTRY; DRUG EFFECT; DRUG POTENTIATION; FEAR; IN VITRO STUDY; METABOLISM; ORAL DRUG ADMINISTRATION; SPRAGUE DAWLEY RAT; STEREOISOMERISM; STRUCTURE ACTIVITY RELATION; SYNTHESIS;

ADMINISTRATION, ORAL; ANIMALS; CEREBRAL CORTEX; CYCLIC AMP; FEAR; GLYCINE; MALE; MOTOR ACTIVITY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; STARTLE REACTION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0348223765     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030967o     Document Type: Article

References (83)

1. Osborne, H. B.; Egebjerg, J.; Nielsen, E.; Madsen, U.; Krogsgaard-Larsen, P. Ligands for Glutamate Receptors: Design and Therapeutic Prospects. J. Med. Chem. 2000, 43, 2609-2645.
2. Cunningham, M. D.; Ferkany, J. W.; Enna, S. J. Excitatory Amino Acid Receptors: A Gallery Of New Targets For Pharmocological Intervention. Life Sci. 1994, 54, 135-148.
3. Hollmann, M.; Heinemann, S. Cloned Glutamate Receptors. Annu. Rev. Neurosci. 1994, 17, 31-108.
4. Nakanishi, S.; Masu, M. Molecular Diversity And Functions Of Glutamate Receptors. Annu. Rev. Biophys. Biomol. Struct. 1994, 23, 319-348.
5. Bockaert, J.; Pin, J. P. Molecular Tinkering of G protein-coupled Receptors: an Evolutionary Success. EMBO J. 1999, 18, 1723-1729.
6. For reviews see: (a) Watkins, J. C.; Collingridge, G. L. Phenylglycine derivatives as antagonists of metabotropic glutamate receptors. Trends Pharmacol. Sci. 1994, 15, 333-342.
7. (b) Pin, J. P.; Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34, 1-26.
8. (c) Roberts, P. J. Pharmacological tools for the investigation of metabotropic glutamate receptors (mGluRs): phenylglycine derivatives and other selective antagonists: un update. Neuropharmacology 1995, 34, 813-819.
9. (d) Conn, P. J.; Pin, P. J. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37, 205-237.
10. (e) Pin, J. P.; De Colle, C.; Bessis, A. S.; Acher, F. New perspectives for the development of selective metabotropic glutamate receptor ligands. Eur. J. Pharmacol. 1999, 375, 277-294.
11. (f) Schoepp, D. D.; Jane, D. E.; Monn, J. A. Pharmacological agents acting at subtypes of metabotropic glutamate receptors. Neuropharmacology 1999, 38, 1431-1476.
12. Nakagawa, Y.; Saitoh, K.; Ishihara, T.; Ishida, M.; Shinozaki, H. (2S,3S,4S)-α-(Carboxycyclopropyl) glycine is a novel agonist of metabotropic glutamate receptors. Eur. J. Pharmacol. 1990, 184, 205-206.
13. Hayashi, Y.; Tanabe, Y.; Aramori, I.; Masu, M.; Shimamoto, K.; Ohfune, Y.; Nakanishi, S. Agonist analysis of 2-(carboxycyclopropyl) glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in chinese hamster ovary cells. Br. J. Pharmacol. 1992, 107, 539-543.
14. Shibuya, A.; Sato, A.; Taguchi, T. Peparation of difluoro analogues of CCGs and their pharmacological evaluations. Bioorg. Med. Chem. Lett. 1998, 8, 1979-1984.
15. Shimamoto, K.; Ohfune, Y. Inversion of cis-substituted α-cyclopropyl acyl anion. Stereoselective entry to the synthesis of a potent metabotropic glutamate agonist, (2S,1′S,2′ S)-2-(carboxycyclopropyl) glycine (L-CCG-I), and its 3′-substituted analogues. SynLett 1993, 919-920.
16. Brabet, I.; Parmentier, M. L.; De Colle, C.; Bockaert, J.; Acher, F.; Pin, J. P. Comparative effect of L-CCG-I, DCG-IV and γ -carboxy-L-glutamate on all cloned metabotropic glutamate receptor subtypes. Neuropharmacology 1998, 37, 1043-1051.
17. Mutel, V.; Adam, G.; Chaboz, S.; Kemp, J. A.; Klingelschmidt, A.; Messer, J.; Wichmann, J.; Woltering, T.; Richards, J. G. Characterization of (2S,2′R,3′R)-2-(2′,3″-[3H]-Dicarboxycyclopropyl) Glycine Binding in Rat Brain. J. Neurochem. 1998, 71(6), 2558-2564.
18. Collado, I.; Pedregal, C.; Mazón, A.; Espinosa, J. F.; Blanco-Urgoiti, J.; Schoepp, D.; Wright, R. A.; Johnson, B.; Kingston, A. (2S,1′S,2′S,3′R)-2-(2′-Carboxy-3′ -methylcyclopropyl) glycine is a potent and selective Metabotropic Group 2 Receptor Agonists with Anxiolytic Properties. J. Med. Chem. 2002, 45, 3619-3629.
19. (a) Pellicciari, R.; Marinozzi, M.; Natalini, B.; Costantino, G.; Luneia, R.; Giorgi, G.; Moroni, F.; Thomsen, C. Synthesis and Pharmacological Characterization of All Sixteen Stereoisomers of 2-(2′-Carboxy-3′ -phenylcyclopropyl)glycine. Focuson(2S,1′S,2′S,3′ R)-2-(2′-Carboxy-3′-phenylcyclopropyl) glycine, a Novel and Selective Group II Metabotropic Glutamate Receptors Antagonist. J. Med. Chem. 1996, 39, 2259-2269.
20. (b) Marinozzi, M.; Natalini, B.; Constantino, G.; Tijskens, P.; Thomsen, C.; Pellicciari, R. Asymmetric Synthesis of Enantiomerically Pure (2S,1′S,2′S,3′R)-Phenylcarboxycyclopropylglycine (PCCG-4): A Potent and Selective Ligand at Group II Metabotropic Glutamate Receptors. Bioorg. Med. Chem. Lett. 1996, 6, 2243-2246.
21. Pellicciari, R.; Costantino, G.; Marinozzi, M.; Macchiarulo, A.; Amori, L.; Flor, P. J.; Gasparini, F.; Kuhn, R.; Urwyler, S. Design, Synthesis and Preliminary Evaluation of Novel 3′-Substituted Carboxycyclopropylglycines as Antagonists at Group 2 Metabotropic Glutamate Receptors. Bioorg. Med. Chem. Lett. 2001, 11, 3179-3182.
22. Ornstein, P. L.; Bleisch, T. J.; Arnold, M. B.; Wright, R. A.; Johnson, B. G.; Schoepp, D. D. 2-Substituted ((1SR,2SR)-2-Carboxycycloprop-1-yl) glycines as Potent and Selective antagonist of group II metabotropic receptors. 1. Effects of alkyl, arylalkyl, and diarylalkyl substitution. J. Med. Chem. 1998, 41, 346-357.
23. Pedregal, C.; Mazón, A.; Collado, I.; Yruretagoyena, B.; Ezquerra, J.; Wright, R. A.; Johnson, B. G.; Schoepp, D. D.; Kingston, A.; Tomlinson, R. 2,3′-Disubstituted 2-(2′-Carboxycyclopropyl) Glycine as Potent and Selective Antagonists of Metabotropic Glutamate Receptors. Bioorg. Med. Chem. Lett. 1998, 8, 2849-2854.
24. Pretsch, E.; Buhlmann, P.; Affolter, C. Tables of spectral data for structure determination, 3rd ed.; Verlag: Berlin, Heidelberg, New York, 2000.
25. Edward, J. T.; Jitrangsri, C. Stereochemistry of the Bucherer-Bergs and Strecker Reactions of 4-tert-Butylcyclohexanone. Can. J. Chem. 1975, 53, 3339-3350.
26. Sorensen, U. S.; Bleisch, T. J.; Kingston, A. E.; Wright, R. A.; Johnson, B. G.; Schoepp, D. D.; Ornstein, P. L. Synthesis and Structure-Activity Relationship Studies of Novel 2-Diarylethyl Substituted (2-Carboxycycloprop-1-yl) Glycines as High-Affinity Group II Metabotropic Glutamate Receptor Ligands. Bioorg. Med. Chem. 2003, 11, 197-205.
27. (a) Doyle, M. P.; Austin, R. E.; Bailey, A. S.; Dwyer, M. P.; Dyatkin, A. B.; Kalinin, A. V.; Kwan, M. M. Y.; Liras, S.; Oalmann, C. J.; Pieters, R. J.; Protopova, M. N.; Raab, C. E.; Roos, G. H. P.; Zhou, Q.-L.; Martin, S. F. Enantioselective intramolecular cyclopropanations of allylic and homoallylic diazoacetamides using chiral dirhodium(II) carboxamide catalysts. J. Am. Chem. Soc. 1995, 117, 5763-5775.
28. (b) Doyle, M. P.; Zhou, Q.-L. Enantioselective catalytic intramolecular cyclopropanation of allylic α-diazopropionates optimized with dirhodium(II) tetrakis[methyl 2-oxazolidinone-4(S or R)-carboxylate]. Tetrahedron: Asymmetry 1995, 6, 2157-2160.
29. (c) Doyle, M. P.; Dyatkin, A. B.; Ruppar, D. A. Enhancement of enantiocontrol/diastereocontrol in catalytic intramolecular cyclopropanation and carbon-hydrogen insertion reactions of diazoacetates with Rh2-(4S-MPPIM)4. Tetrahedron Lett. 1995, 36, 7579-7582.
30. (d) Martin, S. M.; Oalmann, C. J.; Liras, S. Enantioselective, rhodium catalyzed intramolecular cyclopropanations of homoallylic diazoacetates. Tetrahedron Lett. 1992, 33, 6727-6730.
31. Doyle, M. P.; Peterson, C. S.; Zhou, Q.-L.; Nishiyama, H. Comparative evaluation of enantiocontrol for intramolecular cyclopropanation ofdiazoacetates with chiral CuI, RhII and RuII catalysts. Chem. Commun. 1997, 211-212.
32. 6 of the corresponding monoacetate obtained by reaction of 19 with methyllithium and subsequent acetylation.21a
33. Chakraborty, T. K.; Azhar Hussain, K.; Venkat Reddy, G. α-Phenylglycinol as chiral auxiliary in diastereoselective Strecker synthesis of α-amino acids. Tetrahedron 1995, 51, 9179.
34. Schoepp, D. D.; Johnson, B. G.; Salhoff, C. R.; Valli, M. J.; Desai, M. A.; Burnett, J. P.; Mayne, N. G.; Monn, J. A. Selective inhibition of forskolin-stimulated cyclic AMP formation in rat hippocampus by a novel mGluR agonist, 2R,4R-4-amino-pyrrolidine-2,4-dicarboxylate. Neuropharmacology 1995, 34, 843-850.
35. Schoepp, D. D.; Johnson, B. G.; Salhoff, C. R.; McDonald, J. W.; Johnston, M. V. In vitro and in vivo pharmacology of trans- and cis-(±)-1-amino-1,3-cyclopentanedicarboxylic acid: dissociation of metabotropic and ionotropic excitatory amino acid receptor effects. J. Neurochem. 1991, 56, 1789-1796.
36. (a) Flor, P. J.; Lindauer, K.; Puttner, I.; Ruegg, D.; Lukic, S.; Knöfel, R.; Kuhn, R. Molecular cloning, functional expression and pharmacological characterization of the human metabotropic glutamate receptor type 2. Eur. J. Neurosci. 1995, 7, 622-629.
37. (b) Flor, P. J.; Henrich-Noack, P.; Sabelhaus, C. F.; Prass, K.; Dirnagl, U.; Gasparini, F.; Sauter, A.; Rudin, M.; Reymann, K. G. Distinct influence of the group III metabotropic glutamate receptor agonist (R,S)-4-phosphonophenylglycine on different forms of neuronal damage. Neuropharmacology 2000, 39, 911-917.
38. (c) Thomas, N. K.; Wright, R. A.; Howson, P. A.; Kingston, A. E.; Schoepp, D. D.; Jane, D. E. (S)-3,4-DCPG, a potent and selective mGlu8a receptor agonist, activates metabotropic glutamate receptors on primary afferent terminals in the neonatal rat spinal cord. Neuropharmacology 2001, 40, 311-318.
39. (a) Moghaddam, B.; Adams, B. W. Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats. Science 1998, 281, 1349-1352.
40. (b) Aghajanian, G. K.; Marek, G. J. Serotonin-Glutamate Interactions: A New Target for Antipsychotic Drugs. Neuropsychopharmacology 1999, 21 (S6), S122-S133.
41. (c) Cartmell, J.; Monn, J. A.; Darryle, D. D. The Metabotropic Glutamate 2/3 Receptor Agonists LY354740 and LY379268 Selectively Attenuate Phencyclidine versus d-Amphetamine Motor Behavours in Rats. J. Pharmacol. Exp. Ther. 1999, 291, 161-170.
42. (d) Cartmell, J.; Monn, J. A.; Darryle, D. D. Attenuation of specific PCP-evoked behaviors by the potent mGlu2/3 receptor agonist, LY379268 and comparison with the atypical antipsychotic, clozapine. Psychopharmacology 2000, 148, 423-439.
43. (e) Schreiber, R.; Lowe, D.; Voerste, A.; De Vry, J. LY354740 Affects Startle Responding but not Sensorimotor Gating or Discriminative Effects of Phencyclidine. Eur. J. Pharmacol. 2000, 388, R3-R4.
44. (f) Cartmell, J.; Monn, J. A.; Schoepp, D. D. The mGlu2/3 receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur. J. Pharmacol. 2000, 400, 221-224.
45. (g) Cartmell, J.; Kenneth, W. P.; Salhoff, R. C.; Monn, J. A.; Schoepp, D. D. The Potent, Selective mGlu2/3 Receptor Agonist LY379268 Increases Extracellular Levels of Dopamine, 3,4-Dihydroxyphenylacetic Acid, Homovanillic Acid and 5-Hydroxyindole-3-Acetic Acid in the Medial Prefrontal Cortex of the Freely Moving Rat. J. Neurochem. 2000, 75, 1147-1154.
46. (h) Schoepp, D. D.; Maker, G. J. Preclinical Pharmacology of mGlu2/3 Receptor Agonists: Novel Agents for Schizophrenia? Curr. Drug Targets 2002, 1, 215-225.
47. (i) Lahti, A. C.; Weiler, M. A.; Michaelidis, T.; Parwani, A.; Tamminga, C. A. Effects of Ketamine in Normal and Schizophrenic Volunteers. Neuropsychopharmacology 2001, 25, 455-466.
48. (a) Helton, D. R.; Tizzano, J. P.; Monn, J. A.; Schoepp, D. D.; Kallman, M. J. Anxiolytic and side-effects profile of LY354740: A potent, highly selective, orrally active agonist for group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 1998, 284, 651-660.
49. (b) Klodzinska, A.; Chojnacka-Wojcik, E.; Palucha, A.; Branski, P.; Popik, P.; Pilc, A. Potential anti-anxiety, anti-additive effects of LY354740, a selective group 2 glutamate metabotropic receptors agonist in animal models. Neuropharmacology 1999, 38, 1831-1839.
50. (c) Benvenga, M. J.; Overshiner, C. D.; Monn, J. A.; Leander, J. D. Disinhibitory Effects of LY354740, a New mGluR2 Agonist, on Behaviors Suppressed by Electric Shock in Rats and Pigeons. Drug Dev. Res. 1999, 47, 37-44.
51. (d) Shekhar, A.; Keim, S. R. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000, 39, 1139-1146.
52. (e) Pilc, A.; Chojnacka-Wójcik, E.; Tatarczynska, E.; Borycz, J.; Kroczka, B. Stimulation of group II metabotropic glutamate receptor or inhibition of group I ones exerts anxiolytic-like effects in rats. Amino Acids 2000, 19, 81-86.
53. (f) Tizzano, P. J.; Griffey, K. I.; Schoepp, D. D. The anxiolytic action of mGlu2/3 receptor agonist, LY354740, in the fear-potentiated startle in rats is mechanistically distinct from diazepam. Pharmacol., Biochem. Behav. 2002, 73, 367-374.
54. Vardergriff, J.; Rasmussen, K. The selective mGlR2/3 receptor agonist LY354740 attenuates morphine-withdrawal-induced activation of locus coeruleus neurons and behavioral signs of morphine withdrawal. Neuropharmacology 1999, 38, 217-222.
55. (a) Marek, G. J.; Wright, R. A.; Schoepp, D. D.; Monn, J. A.; Aghajanian, G. K. Physiological Antagonism between 5-Hydroxy-tryptamine 2A and Group II Metabotropic Glutamate Receptors in Prefrontal Cortex. J. Pharmacol. Exp. Ther. 2000, 292 (1), 76-87.
56. (b) Gewirtz, J. C.; Marek, G. J. Behavioral Evidence for Interactions between a Hallucinogenic Drug and Group II Metabotropic Glutamate Receptors. Neuropsychopharmacology 2000, 23 (5), 569-576.
57. (c) Gewirtz, J. C.; Chen, A. C.; Terwilliger, R.; Duman, R. C.; Marek, G. J. Modulation of DOI-induced increases in cortical BDNF expression by group II mGlu receptors. Pharmacol., Biochem. Behav. 2002, 73, 317-326.
58. (d) Klodzinska, A.; Bijak, M.; Tokarski, K. Pilc, A. Group II mGlu receptor agonists inhibit behavioural and electrophysiological effects of DOI in mice. Pharmacol., Biochem. Behav. 2002, 73, 327-332.
59. (e) Krystal, J. H.; Sanacora, G.; Blumberg, H.; Anand, A.; Charney, D. S.; Marek, G.; Epperson, C. N.; Goddard, A.; Mason, G. F. Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments. Mol. Psychiatry 2002, 7, S71-S80.
60. (a) Kingston, A. E.; O'Neill, M. J.; Bond, A.; Bruno, V.; Battaglia, G.; Nicoletti, F.; Harris, J. R.; Clark, B. P.; Monn, J. A.; Lodge, D.; Schoepp, D. D. Neuroprotective Actions of Novel and Potent Ligands of Group I and Group II Metabotropic Glutamate Receptors. Ann. New York Acad. Sci. 1999, 438-449.
61. (b) Batagglia, G.; Bruno, V.; Ngomba, R. T.; Di Grezia, R.; Copani, A.; Nicoletti, F. Selective Activation of Group II Metabotropic Glutamate Receptors is Protective Against Excitotoxic Neuronal Death. Eur. J. Pharmacol. 1998, 356, 271-274.
62. (c) Lam, A. G. M.; Soriano, M. A.; Monn, J. A.; Schoepp, D. D.; Lodge, D.; McCulloch, J. Effects of the Selective Metabotropic Glutamate Agonist LY354740 in a Rat Model of Permanent Ischaemia. Neurosci. Lett. 1998, 254, 121-123.
63. (d) Behrens, M. M.; Strasser, U.; Heidingen, V.; Lobner, D.; Yu, S. P.; McDonald, J. W.; Won, M.; Choi, D. W. Selective Activation of Group II mGlu receptors with LY354740 does not Prevent Neuronal Excitotoxicity. Neuropharmacology 1999, 38, 1621-1630.
64. (e) Cai, Z.; Xiao, F.; Fratkin, J. D.; Rhodes, P. G. Protection of Neonatal Rat Brain from Hypoxic-ischemic Injury by LY379268, a Group II Metabotropic Glutamate Receptor Agonist. Neurochem. Int. 1999, 10, 3927-3931.
65. (f) Kingston, A. E.; O'Neill, Lam, A.; Bales, K. R.; Monn, J. A.; Schoepp, D. D. Neuroprotection by Metabotropic Glutamate Receptor Agonists: LY354740, LY379268 and LY389795. Eur. J. Pharmacol. 1999, 377, 155-165.
66. (g) Pizzi, M.; Benarese, M.; Boroni, F.; Goffi, F.; Valerio, A.; Spano, P. F. Neuroprotection by Metabotropic Glutamate Receptor Agonists on Kainate-Induced Degeneration of Motor Neuron in Spinal Cord Slices from Adult Rat. Neuropharmacology 2000, 39, 903-910.
67. (h) Bond, A.; Jones, N. M.; Hicks, C. A.; Whiffin, G. M.; Ward, M. A.; O'Neill, M. F.; Kingston, A. E.; Monn, J. A.; Ornstein, P. L.; Schoepp, D. D.; Logde, D.; O'Neill, M. J. Neuroprotective Effects of LY379268, a Selective mGlu2/3 Receptor Agonist: Investigations into Possible mechanism of Action In Vivo. J. Pharm. Exp. Ther. 2000, 294, 800-809.
68. (i) Mills, C. D.; Xu, G. Y.; McAdoo, D. J.; Hulsebosch, C. E. involvement of metabotropic glutamate receptors in excitatory amino acid and GABA release following spinal cord injury in rat. J. Neurochem. 2001, 79, 835-848.
69. (a) Dolan, S.; Nolan, A. M. Behavioural evidence supporting a differential role for group I and II metabotropic glutamate receptors in spinal nociceptive transmission. Neuropharmacology 2000, 39, 1132-1138.
70. (b) Maione, S.; Oliva, P.; Marabese, I.; Palazzo, E.; Rossi, F.; Berrino, L.; Rossi, F.; Filippelli, A. Periaqueductal gray matter metabotropic glutamate receptors modulate formalin-induced nociception. Pain 2000, 85, 183-189.
71. (c) Popik, P.; Kozela, E.; Pilc, A. Selective agonist of group II glutamate metabotropic receptors, LY354740, inhibits tolerance to analgesic effects of morphine in mice. Br. J. Pharmacol. 2000, 130, 1425-1431.
72. (d) Simmons, R. M. A.; Webster, A. A.; Balra, A. B.; Iyengar, S. Pharmacol., Biochem. Behav. 2002, 73, 419-427.
73. Abe, K.; Saito, H. L-Glutamate Suppresses Amyloid β-Protein-Induced Stellation of Cultured Rat Cortical Astrocytes. J. Neurochem. 2000, 74 (1), 280-286.
74. (a) Attwell, P. J. E.; Kaura, S.; Sigala, G.; Bradford, H. F.; Croucher, M. J.; Jane, D. E.; Watkins, J. C. Blockade of both epileptogenesis and glutamate release by (1S, 3S)-ACPD, a presynaptic glutamate receptor agonist. Brain Res. 1995, 698, 155-162.
75. (b) Abdul-Ghani, A. S.; Attwell, P. J. E.; Kent, N. S.; Bradford, H. F.; Croucher, M. J.; Jane, D. E. Anti-epileptogenic and anticonvulsant activity of L-2-amino-4-phosphonobutyrate, a presynaptic glutamate receptor agonist. Brain Res. 1997, 755, 202-212.
76. (c) Klodzinska, A.; Chojnacka-Wojcik, E.; Pilc, A. Selective group II glutamate metabotropic receptor agonist LY354740 attenuates pentetrazole- and picrotoxin-induced seizures. Pol. J. Pharmacol. 1999, 51, 543-545.
77. (d) Moldrich, R. X.; Jeffrey, M.; Talebi, A.; Beart, P. M.; Chapman, A. G.; Meldrum, B. S. Anti-epileptic activity of group II metabotropic glutamate receptor agonists (-)-2-oxa-4-aminobicyclo[3.1.0.]-hexane-4,6-dicarboxylate (LY389795). Neuropharmacology 2001, 41, 8-18.
78. (a) Konieczny, J.; Ossowska, K.; Wolfarth, S.; Pilc, A. LY354740, a group 2 metabotropic glutamate receptor agonist with potential antiparkinsonian properties in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 1998, 358, 500-502.
79. (b) Wolfarth, S.; Konieczny, J.; Lorenc-Koci, E.; Ossowska, K.; Pilc, A. The role of metabotropic glutamate receptor (mGluR) ligands in parkinsonian muscle rigidity. Amino Acids 2000, 19, 95-101.
80. (c) Greenamyre, J. P. Glutamatergic Influences on the Basal Ganglia. Clin. Neuropharmacol. 2001, 24 (2), 65-70.
81. (d) Murray, T. K.; Messenger, M. J.; Ward, M. A.; Woodhouse, S.; Osborne, D. J.; Duty, S.; O'Neill, M. J. Evaluation of the mGluR2/3 agonist LY379268 in rodent models of Parkinson's disease. Pharmacol., Biochem. Behav. 2002, 73, 455-466.
82. (a) Cartmell, J. J. Pharmacol. Exp. Ther. 1999, 291, 161-170.
83. (b) Cartmell, J. Naunyn-Schmiedeberg's Archives Pharmacology 2000, 361, 39-46.